Patents by Inventor Meiwei Wang

Meiwei Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976054
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: May 7, 2024
    Assignee: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Patent number: 11953500
    Abstract: The present invention provides a detection reagent and therapeutic target for B cell tumor after targeted therapy and related applications. The reagent composition comprises 3 groups of antibodies, with the first group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD24 an antibody, an anti-CD20 antibody, an anti-CD81 antibody, an anti-CD45 antibody; the second group of antibodies including an anti-CD38 antibody, an anti-CD10 antibody, an anti-CD34 antibody, an anti-CD19 antibody, an anti-CD20 antibody, an anti-CD72 antibody, an anti-CD45 antibody; and the third group of antibodies including an anti-cytoplasmic CD79a antibody. The reagent composition of the present invention can be applied for the detection of B-lymphocyte tumors after targeted therapy by flow cytometry.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: April 9, 2024
    Assignees: Synarc Research Laboratory (Beijing) Ltd., HEBEI YANDA LUDAOPEI HOSPITAL
    Inventors: Hui Wang, Man Chen, Aixian Wang, Meiwei Gong, Xueying Wu, Junyi Zhen, Qing Du, Ya Guo
  • Publication number: 20230227482
    Abstract: Tetrahydrocannabinol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: July 20, 2023
    Inventors: Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230165867
    Abstract: The present application relates to imidazolidinone derivatives and medical use thereof, and in particular relates to pyrimidine derivatives represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or co-crystals thereof, a pharmaceutical composition comprising the same, and use of the compound or pharmaceutical composition according to the present application in the manufacture of a medicament for treatment of cancer.
    Type: Application
    Filed: October 14, 2022
    Publication date: June 1, 2023
    Inventors: Yonggang WEI, Xuezhen XU, Hongzhu CHU, Lvxue HE, Feiquan LEI, Jie YAN, Yang HE, Meiwei WANG, Guizhuan SU, Bing LIU, Yi SUN
  • Publication number: 20230059087
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to the compounds represented by general formula (I), or stereoisomers, solvates, metabolites, prodrugs, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of substituents in general formula (I) are the same as those in the description
    Type: Application
    Filed: January 7, 2021
    Publication date: February 23, 2023
    Inventors: Xibing ZHOU, Jing ZHANG, Xuezhen XU, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20230002425
    Abstract: Cannabidiol derivatives and medical use thereof, in particular to compounds represented by general formula (I), or stereoisomers, solvates, metabolites, pharmaceutically acceptable salts or cocrystals thereof, wherein the definitions of the substituents in general formula (I) are the same as those in the description.
    Type: Application
    Filed: January 7, 2021
    Publication date: January 5, 2023
    Inventors: Xuezhen XU, Jing ZHANG, Yonggang WEI, Hongzhu CHU, Fuqiang ZHAO, Guizhuan SU, Meiwei WANG, Yi SUN
  • Publication number: 20220411392
    Abstract: The present invention relates to an amide derivative and use thereof in medicine, and specifically to an amide derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, deuteride, prodrug, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition containing the same, and use of the compound or the composition disclosed herein in preparing an NLRP3 inhibitor.
    Type: Application
    Filed: November 12, 2020
    Publication date: December 29, 2022
    Applicant: Chengdu Baiyu Pharmaceutical Co., Ltd.
    Inventors: Yonggang Wei, Hongzhu Chu, Yue Gao, Lingfeng Xiong, Guizhuan Su, Meiwei Wang, Yi Sun
  • Publication number: 20220402920
    Abstract: The present invention relates to a purine derivative and use thereof in medicine, and in particular to a pyrimidine derivative shown as general formula (I) or a stereoisomer, solvate, metabolite, prodrug, deuteride, pharmaceutically acceptable salt or cocrystal thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of preparation of a DNA-PK inhibitor, wherein the substituents in general formula (I) are defined in the same way as in the specification
    Type: Application
    Filed: December 30, 2020
    Publication date: December 22, 2022
    Inventors: Yonggang Wei, Xuezhen Xu, Hongzhu Chu, Lvxue He, Xiangyu Meng, Meiwei Wang, Guizhuan Su, Bing Liu, Yi Sun